SynchroMed II and SynchroMed EL pumps 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Medtronic 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2013-06-19
  • 사례 출판 날짜
    2013-06-19
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: medtronic synchromed ii and synchromed el pumps the medicines and healthcare products regulatory agency (mhra), united kingdom posted a field safety notice concerning synchromed ii and synchromed el pumps, manufactured by medtronic. within the synchromed pump, feedthroughs are components that provide an electrically insulated path for current to flow from the electronic circuitry to the motor. an electrical short can occur when ions from the drug solution and humidity permeate through the drug pathway tubing inside the pump and interact with the feedthrough over time. an electrical short circuit in a feedthrough may present as a motor stall or low battery reset/alarm and lead to a loss of or reduction in therapy which may result in the return of underlying symptoms and/or withdrawal symptoms. patients receiving intrathecal baclofen therapy are at risk for baclofen withdrawal syndrome, which can lead to a life threatening condition if not promptly and effectively treated. surgical revision to replace or remove the pumps may be required for patients with pumps experiencing repeated motor stalls, low battery resets (with or without safe state), or a premature elective replacement indicator. all synchromed ii and synchromed el pumps can potentially be affected by this issue at any time throughout the life of the device, regardless of drugs used in the pump. the synchromed el has been discontinued and based on medtronic data, at least 90% of the remaining actively implanted synchromed el pumps are near expected end of service. medtronic has assessed reports of internal feedthrough shorting in the synchromed ii pump since its release in 2004. there have been 380 relevant product events from approximately 181,400 pump implants worldwide. medtronic’s analysis of returned products and reports data shows the cumulative failure probability for internal feedthrough shorting to be approximately 0.28% at 48 months and 0.69% at 84 months post implant. for synchromed ii, this issue may be exhibited as one or more of the following: repeated motor stalls with recovery listed in the pump event log, not associated with temporary exposure to a magnetic field (e.G. mri). multiple “reset - low battery” errors (critical alarm) listed in the pump event log. after a reset, the pump may change to “safe state”. while in safe state, the pump does not deliver at a therapeutic rate. premature elective replacement indicator (non-critical alarm), which is one that occurs sooner than expected based on implant duration and flow rate. for synchromed el, this issue may be exhibited as one or both of the following: motor stall as determined by rotor study low battery alarm medtronic does not recommend prophylactic replacement of synchromed ii or synchromed el pumps due to the estimated low occurrence rate, the presence of pump alarms, and the risks associated with replacement surgery. if repeated short duration motor stalls, low battery resets (with or without safe state), or a premature elective replacement indicator occur, replacement surgery should be scheduled for therapy continuation. alternative medical management should be considered if appropriate. furthermore, the manufacturer provided the following ongoing patient management recommendations: continue to monitor patients closely for the return of baseline symptoms. a return of baseline symptoms may potentially indicate pump failure. inform patients about the importance of keeping their pump refill appointments and contacting their physician immediately if the pump alarm sounds or if they notice a change or return of symptoms. remind patients to always carry their patient identification card. reinforce with patients and caregivers information on the signs and symptoms of withdrawal due to therapy cessation, and the importance of contacting their healthcare provider immediately if the identified signs and symptoms appear. the synchromed ii pump is designed with both critical and non-critical alarms. increase the critical alarm interval frequency. the critical alarm interval frequency may be changed to sound every 10 minutes. remind patients, their caregivers, and your appropriate staff members to be alert for pump alarms. at implant or follow-up visits, perform an alarm test to provide an opportunity for patients and caregivers to hear and differentiate between the critical and non-critical pump alarms. for patients with a personal therapy manager (ptm), if there is an active alarm, the ptm will show an alarm code when a bolus is attempted. retrieve and check logs for critical alarm events when interrogating the synchromed ii pump. note that a motor stall with recovery is expected in the event log when the pump is exposed to a strong magnetic field, such as during an mri. medtronic technical services may be contacted for further assistance evaluating critical alarm events on logs. for the synchromed el pump: remind patients, their caregivers, and your appropriate staff members to be alert for the low battery pump alarm. for suspected motor stalls, perform a rotor study to confirm or rule out a motor stall. for details, please refer to mhra website http://www.Mhra.Gov.Uk/safetyinformation/safetywarningsalertsandrecalls/ fieldsafetynotices/con286830 if you are in possession of the product, please contact your supplier for necessary actions. posted on 19 june 2013.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Medtronic SynchroMed II and SynchroMed EL pumps
  • Manufacturer

Manufacturer

  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    DH